Cargando…

Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma

SIMPLE SUMMARY: Immunotherapeutic approaches became a promising treatment option and an intensive field of research in liver cancer. Despite promising results in preclinical studies, only moderate response rates have been reported in phase III clinical trials and predictive biomarkers are still miss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heinrich, Sophia, Castven, Darko, Galle, Peter R., Marquardt, Jens U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563159/ https://www.ncbi.nlm.nih.gov/pubmed/32899197 http://dx.doi.org/10.3390/cancers12092495

Ejemplares similares

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells
por: Castven, Darko, et al.
Publicado: (2021)

Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer—from Tumor Development to Therapeutic Implications
por: Czauderna, Carolin, et al.
Publicado: (2019)

Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas
por: Castven, Darko, et al.
Publicado: (2017)

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome
por: Heinrich, Sophia, et al.
Publicado: (2022)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?
por: Heinrich, Stefan, et al.
Publicado: (2022)

Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies
por: Marquardt, Jens U., et al.
Publicado: (2019)

Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
por: García-Sancha, Natalia, et al.
Publicado: (2021)

The immune contexture of hepatocellular carcinoma predicts clinical outcome
por: Foerster, Friedrich, et al.
Publicado: (2018)

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
por: Manfredi, Giulia Francesca, et al.
Publicado: (2023)

Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023)

Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
por: Weinmann, Arndt, et al.
Publicado: (2015)

Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
por: Zhang, Zengfu, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy
por: Müller, Lukas, et al.
Publicado: (2022)

Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
por: Müller, Lukas, et al.
Publicado: (2023)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
por: Keller, Hilary R., et al.
Publicado: (2017)

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
por: Foster, Jessica B., et al.
Publicado: (2023)

Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver
por: Czauderna, Carolin, et al.
Publicado: (2018)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
por: Hanly, Ailish, et al.
Publicado: (2021)

A new approach to overcoming resistance to immunotherapy: nanotechnology
por: Shao, Jiangbo, et al.
Publicado: (2023)

Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy
por: Skibbe, Kerstin, et al.
Publicado: (2021)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
por: Pietrobono, Silvia, et al.
Publicado: (2021)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Immunotherapies for hepatocellular carcinoma
por: Liu, Justin K. H., et al.
Publicado: (2021)

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
por: Roehlen, Natascha, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Greten, Tim F, et al.
Publicado: (2021)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

Knockdown of BAP31 Overcomes Hepatocellular Carcinoma Doxorubicin Resistance through Downregulation of Survivin
por: Liu, Jingjing, et al.
Publicado: (2023)

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma
por: Shi, Hewen, et al.
Publicado: (2023)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

Overcoming resistance to immunotherapy by teaching old drugs new tricks
por: Perry, John M., et al.
Publicado: (2020)

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
por: Retecki, Kuba, et al.
Publicado: (2021)

Tumor cell p38 inhibition to overcome immunotherapy resistance
por: Luke, Jason J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1sshark487kqb4da416rpkdc0t